A new discovery of how a certain protein is activated in tumor cells may lead to better treatments for some of cancer’s deadliest forms, researchers report.
The finding could eventually lead to possible therapies for the especially dangerous melanoma and pancreatic adenocarcinoma, as well as the most common type of childhood brain cancer and adult skin cancer.
The study appears in the journal Life Science Alliance.
The discovery concerns the GLI1 protein, which is important in cell development but has also been found turned on in various cancers. GLI1 is typically activated by the Hedgehog signaling pathway, known as HH. However, scientists have known for about a decade that crosstalk, or interaction, between HH and the mitogen-activated protein kinase pathway has a role in cancers.
“In some cases, proteins in one pathway can turn on proteins in another,” says lead author A. Jane Bardwell, project scientist in the developmental and cell biology department at the University of California, Irvine.
“It’s a complex system. We wanted to understand the molecular mechanism that leads to GLI1 being activated by proteins in the MAPK pathway.”
GLI1 normally binds tightly with a protein called SUFU. That protein suppresses GLI1, preventing it from penetrating cell nuclei and turning on genes. The scientists examined seven sites on the GLI1 protein that could be phosphorylated, or have a phosphate group transferred onto it.
“We identified three that can be phosphorylated and are involved in weakening the binding between GLI1 and SUFU,” says Lee Bardwell, professor of developmental and cell biology whose laboratory conducted the project. “This process activates GLI1, enabling it to enter the nucleus of cells, where it can cause uncontrolled growth resulting in cancer.”
He notes that phosphorylation of all three sites causes a significantly higher level of GLI1 escape from SUFU than if just one or even two of them receive phosphate groups.
The discovery is a significant step toward more effective and personalized cancer treatments.
“If we can understand exactly what is going on in a certain cancer or particular tumor, it could be possible to develop a drug specific to a specific tumor or individual patient,” Bardwell says. “It would allow us to treat these diseases without the toxicity of basic chemotherapy.”
In addition, many tumors from the same cancer have different mutations among individuals. Eventually, it may be feasible to screen tumors to develop the best approach for each.
Additional coauthors are from Stanford University and UC Irvine.
The National Institute of General Medical Sciences, the National Cancer Institute, the UC Cancer Research Coordinating Committee, and the Damon Runyon Cancer Research Foundation funded the work.
Source: UC Irvine